Gocovri (amantadine) extended release oral capsules provided long-term improvements of motor complications in Parkinson’s disease patients, according to results from a Phase 3 clinical trial.
Gocovri, developed by Adamas Pharmaceuticals, is the only medication approved by the U.S. Food and Drug Administration for the treatment of dyskinesia — involuntary, jerky movements — in Parkinson’s patients who receive levodopa-based therapy, with or without accompanying dopaminergic medications.
In clinical studies, people with PD taking GOCOVRI experienced significantly less dyskinesia, as well as reduced “OFF” time resulting in better movement control.
GOCOVRI™ (amantadine) extended release capsules is the first and only FDA-approved prescription medication indicated to treat dyskinesia (sudden, uncontrolled movements) in people with Parkinson’s disease (PD) who are treated with levodopa therapy, with or without other medicines that increase the effects of dopamine in the brain. It is not known if GOCOVRI is safe and effective in children.